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Abbreviations 
 
VDCC Voltage-dependent calcium channels 
CaV Voltage-gated calcium channel 
HEK Human embryonic kidney cells 
BTZ Benzothiazepines 
DHP Dihydropyridines 
PAA Phenylalkylamines 
qDIL Quaternary Diltiazem 
I Current 
I-V Current-voltage 
V0.5act Voltage of half-maximal current activation 
V0.5inact Voltage of half-maximal current inactivation 
qDev Quaternary devapamil 
IC50 Concentration for 50% inhibition 
act Time constant of current activation 
inact Time constant of current inactivation 
r300 Inactivation during a 300-ms pulse 
 
 
 
 3 
1 CHAPTER I .........................................................................................................9 
1.1 Discovery and cellular role of calcium channels .......................................................9 
1.2 Classification of calcium channels.............................................................................9 
1.2.1 Cardiac L-VGCC structure ..............................................................................13 
1.2.2 L-type (CaV1.2) channels.................................................................................14 
1.1 Purification of L-type channels................................................................................17 
1.2 Calcium channel subunits ........................................................................................18 
1.2.1 Alpha1C ...........................................................................................................18 
1.2.2 Sites of protein phosphorylation ......................................................................20 
1.2.3 Beta subunits....................................................................................................21 
1.2.3.1 Roles of beta (β2) subunits in calcium channel assembly and trafficking...21 
1.2.3.2 Effect of beta subunit on voltage dependence of calcium channels ............23 
1.2.3.3 Effect of beta subunit on calcium channel gating........................................23 
1.2.3.4 Effect of beta subunits on calcium channel pharmacology .........................24 
1.2.4 α2-δ-subunits....................................................................................................24 
1.2.5 The γ subunits ..................................................................................................26 
1.3 Calcium channel antagonists targeting L-type calcium channels ............................26 
1.4 Use-dependent block................................................................................................27 
1.5 References................................................................................................................29 
2 CHAPTER II ......................................................................................................41 
2.1 INTRODUCTION ...................................................................................................42 
2.2 METHODS ..............................................................................................................43 
2.2.1 General Experimental Methods .......................................................................43 
2.2.2 Synthesis of quaternary Diltiazem...................................................................44 
2.2.3 Purity of qDil ...................................................................................................44 
2.2.4 Cell Culture and Transient Transfection..........................................................44 
2.2.5 Ionic Current Recordings and Data Acquisition..............................................45 
 4 
2.3 RESULTS ................................................................................................................47 
2.3.1 Intracellular and extracellular effects of quaternary d-cis-diltiazem ...............47 
2.3.2 qDil interaction with the diltiazem binding site...............................................51 
2.3.3 Modulation of channel gating by quaternary and tertiary diltiazem................54 
2.4 DISCUSSION..........................................................................................................56 
2.4.1 Similar state dependency of Cav1.2 inhibition by qDil and Dil ......................58 
2.5 Conclusions and outlook..........................................................................................59 
2.6 REFERENCES ........................................................................................................61 
3 CHAPTER III.....................................................................................................64 
3.1 INTRODUCTION ...................................................................................................65 
3.2 EXPERIMENTAL PROCEDURES........................................................................66 
3.3 RESULTS ................................................................................................................69 
3.3.1 Model predictions of potential H-bond interactions with Dil..........................69 
3.3.2 Use-dependent block of T1143A. ....................................................................69 
3.3.3 Use-dependent block of other T1143 mutants. ................................................70 
3.3.4 Mutation T1143A does not affect channel gating............................................73 
3.3.5 Frequency dependence of block.......................................................................74 
3.3.6 Putative Diltiazem binding mode—comparison with SAR studies and 
COMFA model. ...............................................................................................................74 
3.4 DISCUSSION..........................................................................................................76 
3.4.1 Threonine 1143 is a strong determinant of Dil sensitivity...............................76 
3.4.2 T1143A displays wild type kinetics.................................................................80 
3.4.3 Other substitutions of T1143 affect channel inactivation. ...............................81 
REFERENCES ....................................................................................................................83 
 5 
4 SUMMARY OF THE THESIS..........................................................................93 
5 ACKNOWLEDGEMENTS ...............................................................................94 
6 C.V .....................................................................................................................95 
 
 6 
 
 
 
 
 
 
 
 
 
 
 
(Dedicated) To my father, the late Shabbir Hussain  
 7 
 
Abstract 
Calcium fluxes through CaV1.2 (L-type) channels determine cellular excitability and initiate 
contractions of muscle cells, release of hormones and neurotransmitters from secretory and 
nerve cells, gene expression, and many other cellular processes. A drug that blocks calcium 
influx through CaV1.2 is the benzothiazepinone (BTZ) diltiazem. Although diltiazem has 
been in clinical use for a long time, its molecular mechanisms and its access pathway to its 
binding site in CaV1.2 are not fully understood. To identify the access route of diltiazem to its 
putative binding site, the quaternary diltiazem analog qDil was synthesised and applied to 
either the extra- or intracellular site of the membrane. Intracellularly applied qDil induced a 
concentration- and use-dependent block suggesting an intracellular access path. During my 
studies a novel high affinity qDil binding site was identified by molecular modelling and 
mutational analysis. Substitution of  threonine to alanine  in  position 1143 (T1143A) of the 
α1-subunit of CaV1.2 diminished the qDil block at low (0.2Hz) as well as high frequency 
(1Hz) depolarization pulses. Mutation T1143A also reduced channel block by the clinically 
used tertiary diltiazem and a quaternary PAA (qDevapamil). T1143A affected neither 
activation nor inactivation of   CaV1.2, supporting the view that this residue forms part of the 
diltiazem binding pocket on CaV1.2.  
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Zusammenfassung 
Der Einstrom von Calcium durch spannungsabhängige Cav1.2 Kanäle reguliert Erregung und 
Kontraktilität der Muskulatur, die Freisetzung von Hormonen und Neurotransmittern aus 
sekretorischen Zellen oder Nervenzellen und eine Vielzahl anderer zellulärer Prozesse. 
Dieser Calciumeinstrom kann durch Calciumkanalantagonisten dreier verschiedener Klassen, 
Phenylalkylamine (PAA), 1,4 Dihydropyridine (DHPs), und Benzothiazepine (BTZs) 
inhibiert werden. Diltiazem (Dil), ein Vertreter der Benzothiazepine, wird bereits lange Zeit 
therapeutisch verwendet. Bislang konnten jedoch die molekularen Wirkungsmechanismen 
und der Zugangsweg („access path“) von Diltiazem zu seiner hochaffinen Bindungsstelle in 
Cav1.2 nicht geklärt werden. Um den extra- bzw. intrazellulären Zugang von Dil zu seiner 
Bindungsstelle zu untersuchen, wurde das quaternäre Diltiazem-Analogon qDil synthetisiert 
und entweder extrazellulär oder intrazellulär appliziert. Die intrazelluläre Applikation 
erzeugte einen konzentrationsabhängigen ‚Use-dependent Block‘, was einen intrazellulären 
Zugang zur Bindungsstelle nahelegt. Darüber hinaus konnte durch meine Studien mittels 
Mutationsanalyse und molekularem Modeling eine neue, hoch affine, Bindungsdeterminante 
von Dil identifiziert werden. Die Substitution von Threonin durch Alanin an der Position 
1143 (T1143A) im Cav1.2 verringert den Block von qDil sowohl bei nieder- (0,2 Hz) als auch 
hochfrequenten (1 Hz) Depolarisationspulsen. Außerdem reduziert T1143A den Block von 
dem klinisch verwendetem tertiären Diltiazem und quarternären Phenylakylaminen 
(qDevapamil). T1143 hatte weder Einfluss auf die Aktivierung noch die Inaktivierung der 
Cav1.2 Kanäle. Die reduzierte Wirkung von Dil an der T1143A Mutante ist somit nicht über 
allosterische Mechanismen (Konformationsänderungen des Moleküls) zu erklären. Diese 
Befunde stützen die Hypothese, dass T1143 eine wichtige Bindungsdeterminante von Dil auf 
Cav1.2 darstellt. 
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1 CHAPTER I 
 
1.1 Discovery and cellular role of calcium channels 
Voltage-dependent calcium channels (VDCC) are membrane proteins that are key transducers 
of electrical signaling. They convert the depolarization of the cell membrane into an influx of 
calcium ions into the cell. This incoming calcium initiates a large variety of cellular events 
such as action potentials, excitation-contraction coupling, neurotransmission, secretion, gene 
expression and others (Catterall 2000). These channels are ubiquitously distributed 
throughout cellular life. The influx of calcium through them is very crucial for the 
maintenance of cellular homeostasis and other regulatory events. Calcium channels are 
expressed in excitable cells (nerve, muscle) but are also found in many cells that are not 
traditionally considered excitable, e.g cells of the immune system (Cahalan et al. 2001). Paul 
Fatt and Bernard Katz first identified calcium channels in crustacean muscle, when they left 
the Na+ out of their bathing medium and found that the muscle still generated action 
potentials (Fatt and Katz 1953). Harald Reuters was the first to record the calcium current in 
Purkinje fibers under voltage clamp (Reuter 1967).  
 
1.2 Classification of calcium channels  
Initially, two main types were distinguished on the basis of their voltage dependence and 
electrophysiological properties in low-voltage activated (LVA) and high-voltage activated 
(HVA) calcium channels. First evidence of these two distinct types of voltage-gated calcium 
channels came in 1975 from experiments of Hagiwara, Ozawa and Sand with the two-
microelectrode voltage-clamped method on starfish eggs (Hagiwara et al., 1975). They 
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demonstrated that calcium channels are activated by small depolarizations of the membrane 
(LVA) and large depolarizations of the membrane (HVA) (Hagiwara et al, 1975). Until now 
10 genes have been identified encoding α1-subunits of voltage-gated calcium channels. 
Alignment of their deduced amino acid sequences suggests that gene duplication and 
divergence of an ancestral calcium channel gene gave rise to LVA and HVA subfamilies and 
Cav1 and Cav2 subfamilies arose from further duplication of the HVA gene (Perez-Reyes 
2003). 
 
Figure 1. Evolutionary tree of voltage-gated Ca2+ channels 
*Figure adapted from Perez-Reyes (2003) 
 
In 1982, Tsien et al. subdivided calcium channels into three distinct classes on the basis of 
their slope conductances and activation and inactivation properties. The different classes were 
named T-type (LVA), N-type and L-type (both HVA) channels. The L-type channels display 
a large unitary conductance for Ba2+, supporting long-lasting channel openings and are found 
in myocardial  cells (Reuter et al. 1982). The T-type channels conduct tiny (small amplitude) 
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unitary currents giving  rise to a transient average current with  a characteristically slow 
deactivation following sudden depolarization (Armstrong and Matteson 1985) and also were 
shown in heart cells (Nilius et al. 1985). Lastly, the N-type channels were found in neurons, 
they had an intermediate conductance to Ba2+ (Williams et al. 1992). 
 
Table 1: Detailed characteristics of calcium channels  
Channel 
Protein 
Calcium 
current 
Gene 
Name 
and 
Human 
chromos
ome 
Localization Specific 
antagonist 
Cellular functions 
 
Cav 1.1 
 
 
L  
CACNA
1S  
1q31-32 
 
Skeletal 
muscle; 
transverse 
tubules 
Dihydropyridines  
Phenylalkylamines  
Benzothiazepines 
Excitation 
contraction coupling 
Cav1.2 
 
L   CACNA
1C  
12p13.3 
 
heart 
smooth 
muscle 
brain 
heart  
pituitary 
adrenal 
Dihydropyridines  
Phenylalkylamines  
Benzothiazepines 
Excitation-
contraction 
coupling, hormone 
release; regulation 
of transcription; 
synaptic integration 
Cav 1.3 
 
L  
 
CACNA
1D  
3p14.3 
 
brain, 
pancreas, 
kidney, 
ovary, 
 cochlea 
 
Dihydropyridines  
Phenylalkylamines  
Benzothiazepines 
Hormone release; 
regulation of 
transcription; 
synaptic regulation; 
cardiac pacemaking; 
hearing 
neurotransmitter 
release from sensory 
cells 
CaV1.4 
 
L  
 
CACNA
1F 
Xp11.23 
 
Retinal rod 
and bipolar 
cells; spinal 
cord; adrenal 
gland; mast 
cells 
Dihydropyridines 
Phenylalkylamines 
Benzothiazepines 
Neurotransmitter 
release from 
photoreceptors 
CaV2.1 P/Q CACNA
1A  
19p13 
 
Nerve 
terminals and 
dendrites; 
neuroendo-
crine cells 
ω-Agatoxin IVA Neurotransmitter 
release; dendritic 
Ca2+ transients 
hormone release 
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CaV2.2  N CACNA
1B 
9q34 
 
Nerve 
terminals and 
dendrites; 
neuroendo-
crine cells 
ω-Conotoxin-
GVIA 
Neurotransmitter 
release; dendritic 
Ca2+ transients 
hormone release 
 
CaV2.3 
 
R 
CACNA
1E 
1q25-31 
 
Neuronal cell 
bodies and 
dendrites 
SNX-482 Repetitive firing; 
dendritic calcium 
transients 
CaV 3.1 
 
T CACNA
1G 
17q22 
 
Neuronal cell 
bodies and 
dendrites; 
cardiac and 
smooth 
muscle 
myocytes 
None Pacemaking 
repetitive firing 
* Table from Ertel et al. (2000), with changes 
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1.2.1 Cardiac L-VGCC structure 
 
The L-VGCCs are transmembrane protein complexes comprising the pore forming α1, and 
auxiliary α2δ, β, and, in some tissues, γ subunits Fig 2. Upon membrane depolarization they 
allow calcium influx into the cell (Catterall 2000). In excitable tissues, Ca2+ channels 
invariantly contain α1, α2δ, β, subunits. The accessory subunits α2δ, β, are sparingly bound 
to the α1 subunit and modulate the biophysical properties and promote trafficking of the α1 
subunit to the membrane (Brice et al. 1997, Singer et al. 1991, Meir and Dolphin 2002). 
 
 
   
Figure 2. Schematic structure of VGCC  
The principal α1-subunit is a transmembrane protein containing a conducting pore, lined with 
highly conserved glutamate residues. Passage of calcium ions upon opening of the α1-subunit 
is further regulated by auxiliary subunits: the intracellular β-subunit, the transmembrane γ-
subunit and a complex of the extracellular α2-subunit and the transmembrane δ-subunit, 
connected by a disulfide bridge. 
*Image adapted from:  www.ipt.med.tu-muenchen.de 
 
Cardiac contraction is initiated by the influx of calcium through L-type calcium channels 
(LTCC) of transverse tubules (T-tubules) in the cell membrane. The small amount of Ca2+ 
influx through LTCC triggers a large-scale Ca2+ release from the sarcoplasmic reticulum (SR) 
through ryanodine receptors (RyR2) (Bers 2002). Calcium then associates with troponin C in 
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the sarcomere and stimulates contraction (systole). The increase in cytoplasmic Ca2+ 
concentration will induce muscle contraction. To enable relaxation, intracellular Ca2+ is 
pumped back into the SR via SR Ca2+-ATPase (SERCA2a), which is regulated by 
phospholamban (PLB), or extruded from the cell via the Na+/Ca2+-exchanger (Bers 2002) 
(Fig 3).  
 
 
 
 
 
Figure 3. Ca2+ transport in ventricular myocytes. 
The inset shows the time course of action potential, Ca2+ transient and contraction measured 
in a rabbit ventricular myocyte at 37 °C. NCX, Na+/Ca2+ exchange; ATP, ATPase; PLB, 
phospholamban; SR, sarcoplasmic reticulum. 
*Figure adapted from Bers (2002)  
 
 
1.2.2 L-type (CaV1.2) channels 
Detailed properties of L-type calcium channels are given in Table 2. 
 15 
 
Properties of L-type (CaV1.2) channels 
Channel name CaV1.2 
Description Voltage-gated calcium channel with α1-subunit. Other names: α1C, muscle 
dihydropyridine receptor. 
Molecular 
information 
 Human: 2169aa, L29529 (cardiac; PMID: 8392192), 2138aa, Z34815 
(fibroblast; PMID: 1316612); 2138aa, AF465484 (jejunum; PMID: 
12176756); chr. 12p13.3, CACNA1C, LocusID: 775 
 Rat: 2169aa, M59786 (aortic smooth muscle; PMID: 2170396); 
2140/2143aa, M67516/M67515 (brain; PMID: 1648941); chr. 4q42, 
Cacna1c, LocusID: 24239 
 Mouse: 2139aa, L01776 (brain; PMID: 1385406); chr. 6, Cacna1c, 
LocusID: 12288 (see ‘Comments’ 
Associated 
subunits 
α2δ, β, γ 
Functional 
assays 
Patch-clamp (whole-cell, single-channel), calcium imaging, cardiac or 
smooth muscle contraction hormone secretion 
Current ICa,L 
Conductance  Ba2+ (25pS) > Sr2+ = Ca2+ (9pS) 
Ion selectivity  Ca2+ > Sr2+ > Ba2+ >> Mg2+ from permeability ratios 
Activation Va = –17 mV (in 2 mM Ca2+; HEK cells); –4 mV (in 15 mM Ba2+; HEK 
18.8 mV (in 5 mM Ba2+; HEK cells and Xenopus oocytes); τa = 1 ms at +10 mV 
Inactivation Vh = –50 to –60 mV (in 2 mM Ca2+; HEK cells), –18 to –42 mV (in 5-15 
mM Ba2+; HEK cells); τfast = 150 ms, τslow = 1100 ms; 61%  
inactivated after 250 ms in HEK cells (at Vmax in 15 mM Ba2+); 70%  
inactivation after 1 s (at Vmax in 2 mM Ca2+); inactivation is accelerated 
with Ca2+ as charge carrier (calcium-dependent inactivation: 86% 
 16 
inactivated after 250 ms) 
Activators BayK8644, dihydropyridine agonists, FPL64176 
Gating 
modifiers 
Dihydropyridine antagonists (e.g., isradipine, IC50 = 7 nM at –60 mV; 
nimodipine, IC50 = 139 nM at –80 mV) 
Blockers Nonselective: Cd2+  ; selective for CaV1.x: devapamil (IC50 = 50 nM in 10 
mM Ba2+ at –60 mV) and other phenylalkylamines; diltiazem (IC50 = 33 
µM in 10 mM Ba2+ at –60 mV and 0.05Hz)  
Radioligands (+)-[3H]isradipine (Kd < 0.1 nM) and other dihydropyridines; (–)-
[3H]devapamil (Kd = 2.5 nM), (+)-cis-[3H]diltiazem (Kd = 50 nM) 
Channel 
distribution 
Cardiac muscle, smooth muscle (including blood vessels, intestine, lung, 
uterus); endocrine cells (including pancreatic β-cells, pituitary); neurones; 
subcellular localization: concentrated on granule-containing side of 
pancreatic β-cells; neurons (preferentially somatodendritic) 
Physiological 
functions 
Excitation-contraction coupling in cardiac or smooth muscle, action 
potential propagation in sinoatrial and atrioventricular node, synaptic 
plasticity, hormone (e.g., insulin) secretion 
Mutations and 
pathophysiology 
Required for normal embryonic development (mouse, zebrafish); de novo 
G406R mutation in alternative exon 8A in 1 allele causes Timothy 
syndrome20 
Pharmacological 
significance 
Mediates cardiovascular effects of clinically used Ca2+ antagonists; high 
concentrations of dihydropyridines exert antidepressant effects through 
Cav1.2 inhibition 
Comments Tissue-specific splice variants exist; in addition to cardiac channels, 
smooth muscle and brain channels have been cloned; the gene for Cav1.2 
was first isolated and characterized in rabbit heart (2171aa, P15381, 
X15539) 
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From international Union of Pharmacology. XLVIII. Nomenclature and 
Structure-Function Relationships of Voltage-Gated Calcium Channels 
 William A. Catterall, Edward Perez-Reyes, Terrance P. Snutch, and Joerg 
Striessnig, Pharmacol. Rev. 2005 57: 411-425 
aa, amino acids; chr., chromosome; HEK, human embryonic kidney. 
* Table from Catterall et al (2005)  
 
1.1 Purification of L-type channels 
Purification of Ca2+ channels skeletal muscle began with isolation of the Ca2+ channel protein 
from transverse tubule membranes, in an approach to use high-affinity binding to 
dihydropyridine Ca2+ channel antagonists to identify the channel protein (Borsotto et al. 
1985; Curtis and Catterall 1984). To avoid native subunit associations, Ca2+ channels were 
solubilized in a mild detergent and subsequently purified by a combination of ion-exchange 
chromatography, affinity chromatography on wheat-germ agglutinin Sepharose, and 
sedimentation through sucrose gradients (Curtis and Catterall 1984). A heterogeous α-subunit 
band (Borsotto et al. 1985; Curtis and Catterall 1984), 50-kDa associated β-subunits and 33-
kDa γ-subunits were identified as components of the Ca2+ channel in the initial purification 
studies. Later studies demonstrated that the heterogenous α-subunit band contained not only 
the main α1-subunits with an obvious molecular mass of 175 kDa but also a disulfide-linked 
dimer of α2-δ subunits with apparent molecular masses of 143 kDa and 27 kDa, respectively, 
as illustrated in the SDS-PAGE in Fig 4A (Hosey et al. 1987; Leung et al. 1987; Sieber et al. 
1987; Takahashi et al. 1987b; Vaghy et al. 1987).  
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Figure 4. Biochemical properties of skeletal muscle Ca2+ channels  
A. Summary of the biochemical properties of purified skeletal muscle Ca2+ channels. Lanes 1 
and 2, silver stain of polypeptides; lane 3, staining with an antibody against the α1-subunit; 
lane 4, staining with concanavalin A, a lectin binding high mannose N-linked carbohydrate 
chains; lane 5, staining with wheat germ agglutinin, a lectin staining N-linked complex 
carbohydrate chains; lane 6, photoaffinity labeling with azidopine, a photoreactive 
dihydropyridine; lane 7, photoaffinity labeling with TID, a hydrophobic probe of the 
transmembrane regions of proteins; lane 8, phosphorylation by cAMP-dependent protein 
kinase (Takahashi et al., 1987). B. The subunit structure of Ca2+ channels purified from 
skeletal muscle is illustrated. The model is updated from the original description of the 
subunit structure of skeletal muscle Ca2+ channels Takahashi et al., (1987). 
*Figure adpted from Catterall, Landes Bioscience; (2000) 
 
 
1.2 Calcium channel subunits 
1.2.1 Alpha1C 
The α1-subunit of skeletal muscle Ca2+ channels was cloned by library screening based on 
amino acid sequence (Tanabe et al. 1987). The calcium channel α1-subunit 170-240 kDa 
consists of 4 homologous motifs (I-IV), each composed of 6 membrane-spanning α-helices 
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(termed S1 to S6) linked by variable cytoplasmic loops (linkers) between the S5 and S6 
segments Fig. 5 (Bodi et al. 2005). To date, 10 α1 subunit coding genes have been identified 
and separated into four classes: CaV1.1 (α1S), 1.2 (α1C), 1.3 (α1D), and 1.4 (α1F) (see also 
Table 1). Only the α1C (dihydropyridine-sensitive [DHP-sensitive]) subunit is expressed in 
high levels in cardiac muscle. CaV2.1 (α1A), 2.2 (α1B), and 2.3 (α1E) form P/Q-, N-, and 
more likely R-type channels, respectively, and are all found specifically in brain (Bodi et al. 
2005). They are principally responsible for synaptic transmission initiation at fast synapses in 
the nervous system (Yokoyama et al. 2005). 
 
 
Figure 5. Structural organization of L-VGCCs 
The membrane topological architecture of the core subunits,   the auxiliary subunits with 
structural domains, and their interactions which are common to all VGCC types, are shown. 
The main structure of the pore forming α1 subunit is composed of four homologous repeating 
domains (I–IV), each of which consists of six putative transmembrane motifs (S1–S6). The 
cytoplasmic loops are usually named according to the domains they link.  
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*Figure adapted from Bodi et al (2005) 
 
The α1 subunit form the ion-conducting pore, contains gating machinery, voltage sensor, and 
the drugs binding sites (Carafoli et al. 2001; Catterall 2000; Takahashi and Catterall 1987). 
The pore has high affinity with Ca2+ ions due to conserved glutamate (EEEE) which are 
arranged in asymmetric manner (Klockner et al. 1996; Koch et al. 2000; Mikala et al. 1993). 
The fourth transmbrane segment of each motif is positively charged highly conserved, and is 
likely to form an α-helix containing every third or fourth basic (Arg or Lys) residue 
(Bezanilla 2002).  
 
1.2.2 Sites of protein phosphorylation 
The α1-subunits of skeletal muscle Ca2+ channels are substrates for phosphorylation by 
cAMP-dependent protein kinase and a number of other protein kinases (Curtis and Catterall 
1985; Jahn et al. 1988; Nastainczyk et al. 1987; O'Callahan et al. 1988). It has been shown 
that cAMP-dependent protein kinase phosphorylates skeletal muscle L-type Ca2+ channels 
and enhances their activation (Arreola et al. 1987; Schmid et al. 1985). Repetitive 
depolarization of cultured skeletal muscle cells causes a dramatic cAMP-dependent 
potentiation of Ca2+ currents (Fleig and Penner 1996; Sculptoreanu et al. 1993). Increases in 
both the number of functional Ca2+ channels and in the activity of single Ca2+ channels were 
detected after phosphorylation by cAMP-dependent protein kinase in single-channel 
recording experiments in planar bilayer membranes (Flockerzi et al. 1986; Hymel et al. 
1988). Thus, the α1-subunit of the purified Ca2+ channel contains the sites at which cAMP-
dependent protein phosphorylation modulates channel function in vitro (Catterall 2000). 
Regarding phosphorylation sites, earlier it was shown that Ser 687, located in the intracellular 
loop between domains II and III, is the most rapidly phosphorylated site in the truncated form 
of the α1-subunit in purified Ca2+ channel preparations (Rohrkasten et al. 1988; Rotman et al. 
1992). Whereas later, it was clearly revealed in time-course experiments that a Ser1854 near 
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the C-terminal portion of full-length α1212 is the most intensely and rapidly phosphorylated 
(Rotman et al. 1995). 
 
1.2.3 Beta subunits 
The β-subunits are hydrophilic proteins that are not glycosylated and therefore are likely to be 
located on the intracellular side of the membrane Fig 5 (Takahashi et al. 1987). The first 
CaVβ subunit to be identified, now called CaVβ1a, was observed as a 54 kDa subunit in the 
purified skeletal muscle DHP receptor calcium channel complex (Takahashi et al. 1987b) and 
its gene was cloned following partial sequencing of the protein (Ruth et al. 1989). The 
existence of four different β genes (β1-β4) and extensive differential splicing, especially of β1 
and β2 transcripts, give rise to multiple isoforms (Foell et al. 2004). The β subunit is firmly 
bound to a highly conserved motif in the cytoplasmic linker between repeats I and II (AID) of 
all cloned high voltage–gated α1 subunit isoforms, via an 18 amino acid motif called the α-
interaction domain (AID) Fig 4 (Pragnell et al. 1994),  and also to a secondary site 
(Opatowsky et al. 2003). On the β-subunit, a 41-amino acid sequence beta interaction domain 
(BID) was identified as the minimal sequence required to drive α1 subunit expression (de 
Waard and Rooijers 1994). 
 
1.2.3.1 Roles of beta (β2) subunits in calcium channel assembly and trafficking 
It has been shown that the beta subunit has marked effects on the properties of HVA α1-
subunits including current amplitude, modification of channel kinetics, and targeting of 
complex to the plasma membrane (Brice et al 1997, Singer et al 1991). The antisense-induced 
depletion of CaVβ subunits from Dorsal root ganglia (DRGs) results in a reduction of 
amplitude of endogenous calcium currents, and slowed kinetics of activation (Berrow et al 
1995, Campbell et al 1995).  
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It has been demonstrated that all CaVβ-subunits enhance the functional expression of HVA 
α1-subunits (Birnbaumer et al. 1998). This could in theory attributed to an increase in the 
open probability, single-channel conductance, number of functional channels inserted into the 
plasma membrane, or a combination of several processes (Dolphin 2003).  
Initially there was some controversy concerning the effect of CaVβ subunits on the number of 
channels in the plasma membrane. For instance, initial studies in Xenopus oocytes showed 
that for CaV1.2 and CaV2.3, the CaVβ-subunits had no effect on the voltage-dependence of 
charge movement (visualized as gating current), and did not increase the total amount of 
charge transferred, which is a measure (indication) of the number of voltage sensors moving 
in the membrane, and therefore of channels inserted into the membrane (Olcese et al. 1996). 
However, it was found that β-subunits hyperpolarized the voltage dependence of the ionic 
current (Olcese et al. 1996). Thus, the β subunits produced an increase in the ratio of charge 
movement to ionic current, and were said to improve the coupling between voltage sensor 
movement and channel opening (Neely et al. 1993; Olcese et al. 1996). In contrast, other 
groups have found that co-expression of a β-subunit did increase the charge movement 
associated with CaV1.2 gating (Colecraft et al. 2002; Josephson and Varadi 1996). 
Furthermore, many groups have found that CaVβ-subunits have a chaperone like effect, 
promoting functional expression of the CaV2.1, 2.2, and 2.3 subunits at the plasma membrane 
of mammalian cells, and increasing localization of the channels at the plasma membrane 
(Bichet et al. 2000; Brice et al. 1997; Raghib et al. 2001; Yamaguchi et al. 1998). Recently it 
was shown that an increase of (rat brain) CaV1.2 channel density was positively influenced by 
PI3K and β2a (Viard et al. 2004). It was shown that β1-KO mice suffer from impaired EC 
coupling and early lethality (Gregg et al. 1996), clearly indicate that β1 subunit is crucial in 
EC coupling. The exact mechanism of EC coupling is still not fully understood, but it is 
possible that the deficiency in the assembly process of the α1/β1 complex results in the 
degradation of the α1 subunit (Gregg et al. 1996). The role of the β2 subunit in EC coupling 
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is unclear (S. L. Ball et al., 2002) and β3-null mice have no detectable abnormalities in the 
heart (Murakami et al. 2000). 
Different splice variants of the β subunits namely β2a and β2b, have been shown to regulate 
Cav1.2 function (Chien et al. 1996; Qin et al. 1998) . 
 
1.2.3.2 Effect of beta subunit on voltage dependence of calcium channels 
It is well established that all β-subunits affect the voltage dependence of activation of all 
HVA calcium channels (Birnbaumer et al. 1998; Canti et al. 2000; Jones et al. 1998). 
For steady-state inactivation differences are apparent, both between different α1-subunits and 
different β-subunits. There is little difference between different β-subunits and splice variants 
in their ability to shift the steady-state inactivation for CaV1.2 (Jones et al. 1998; Takahashi et 
al. 2003). In contrast, all except palmitoylated β2a hyperpolarize the voltage dependence of 
steady-state inactivation for CaV2.3 and CaV2.3 (Birnbaumer et al. 1998; Canti et al. 2000; 
Jones et al. 1998). 
 
1.2.3.3 Effect of beta subunit on calcium channel gating 
It was reported that β-subunits influence all kinetic processes and have a marked effect on 
open probability, largely by reducing the mean closed time (Colecraft et al. 2002). In case of 
CaV2.3 the kinetics of current activation are little affected by the expression of different β-
subunits (Jones et al. 1998; Meir and Dolphin 2002). It was also observed by other groups 
that for CaV2.2 single channels, the distribution of latencies to first opening of CaV2.2 
channels and the mean open and closed times were similar for both β1b and β2a-subunits 
(Meir and Dolphin 2002). However, the inclusion of the β2a-subunit led to channels with an 
additional phase of slow activation, which may represent slow exit from an inactivated state 
(Meir and Dolphin 2002). 
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As VDCC α1-subunits contain inherent determinants of voltage-dependent inactivation (Cens 
et al. 1999; Herlitze et al. 1997; Spaetgens and Zamponi 1999; Zhang et al. 1994), association 
with different β subunit isoforms dictates their overall inactivation rate (Meir and Dolphin 
2002; Olcese et al. 1994). With HVA at the whole cell level, coexpression of β1b, β2a, β2e, 
or β4 subunits generally decreased the inactivation rate, whereas β3 enhanced inactivation, 
compared to the α1-subunit expressed alone (Dolphin 2003). 
 
1.2.3.4 Effect of beta subunits on calcium channel pharmacology  
Many drugs, such as verapamil and mibefradil, bind preferentially to inactivated calcium 
channels, and therefore their ability to inhibit the channels will be indirectly affected by the 
β-subunit complement because of their differential effects on inactivation (Berjukow et al. 
2000; Lacinova et al. 1995; Zamponi et al. 1996). 
 
1.2.4 α2-δ-subunits 
During purification of skeletal muscle calcium channels, a disulfide-linked dimer of α2-δ 
subunits, with apparent molecular masses of 143 kDa and 27 kDa, respectively, was seen 
(Hosey et al. 1987; Leung et al. 1987; Sieber et al. 1987; Takahashi et al. 1987a; Vaghy et al. 
1987). Protein sequencing has shown that α2 and δ are the product of a single gene, termed 
the α2δ gene, and are separated by proteolytic cleavage (De Jongh et al. 1990; Ellis et al. 
1988; Jay et al. 1991). Until now, four genes encoding α2-δ-subunits have been identified and 
cloned α2/δ1, 2, 3, 4 (De Jongh et al. 1990; Qin et al. 2002). α2δ-1 was initially cloned from 
skeletal muscle and showed a fairly ubiquitous distribution (Barclay et al. 2001; Ellis et al. 
1988; Gao et al. 2000; Qin et al. 2002). It possesses a high-affinity binding site for 
gabapentin (GABA-antagonists), which are widely used to treat epilepsy, sleep disorders, 
pain, and many other neurological conditions (Luo et al. 2002; Marais et al. 2001; Sutton et 
al. 2002). The α2δ-2 cloned from brain has also some affinity for gabapentin (Bodi et al. 
 25 
2005). α2/δ2 deficient mice  exhibit neurological dysfunction, such as enhanced seizure 
susceptibility and cardiac abnormalities, namely a liability to develop bradycardia (Ivanov et 
al. 2004). α2δ-3 subunits were also cloned from brain (Barclay et al., 2001: Klugbauer et al., 
1999; Qin et al., 2002). The human α2/δ4 subunit (is localized in colon, fetal liver, pituitary, 
and adrenal gland) is associated with the CaV1.2 α1C and β3 subunits (Qin et al., 2002). 
Several reports have shown that α2δ-subunits increase the expression of many HVA α1- and 
β-subunit combinations, and all α2δ-subunits seem to have similar effects on current 
amplitude (Canti et al 2003). For example, the peak CaV1.2 current amplitude is increased 
threefold by coexpression of α2δ (Felix et al., 1999). Also, α2δ-1 increases the amount of 
CaV1.2 subunit protein associated with the plasma membrane in Xenopus oocytes used for 
heterologous expression (Shistik et al. 1995). α2δ-2 increases CaV2.2, CaV2.1 and CaV1.2 
currents  by about threefold in both mammalian cells and Xenopus oocytes (Canti and 
Dolphin 2003; Canti et al. 2005; Davies et al. 2006; Gao et al. 2000). Knock out of full-
length α2δ-2 produced an epileptic and ataxic phenotype (Barclay et al. 2001; Meier 1968), 
another link between α2δ-subunits and disease relates to their involvement in neuropathic 
pain. It was shown that both α2δ-1 and α2δ-2 are present in rat dorsal root ganglion neurons 
(DRGs) (Cole et al. 2005), and there is an upregulation of α2δ-1 protein and mRNA both in 
DRGs and in spinal cord on the same side as an experimental nerve crush injury (Luo et al. 
2001; Newton et al. 2001; Wang et al. 2002). This upregulation correlates with the onset of 
allodynia, in which the sensation of non-noxious touch causes pain-related behaviours, and 
subsequent downregulation correlates with the gradual loss of allodynia in this model (Devies 
et.al. 2007). In addition, intrathecal administration of antisense oligonucleotides directed 
against α2δ-1 mRNA reduces both the experimental upregulation of protein and pain-related 
behaviours (Li et al. 2004). It has recently been shown that mice overexpressing α2δ-1 show 
allodynia in the absence of nerve injury (Li et al. 2006). 
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1.2.5 The γ subunits 
The γ-subunit of skeletal muscle Ca2+ channels is a hydrophobic glycoprotein with an 
apparent molecular mass of 30kDa without deglycosylation and 20kDa following 
deglycosylation (Sharp and Campbell 1989; Takahashi et al. 1987b). To date, 8 genes 
encoding gamma subunits γ1-γ8 have been identified (Kang and Campbell 2003). 
 
1.3 Calcium channel antagonists targeting L-type calcium channels 
Calcium channel antagonists (CA) are a chemically, pharmacologically and therapeutically 
heterogeneous group of drugs prominent both as cardiovascular therapeutic agents and as 
molecular tools (Triggle 2007). The calcium channel blockers are divided into three main 
classes: phenylalkylamines (PAA; e.g. verapamil), dihydropyridines (DHP; e.g. nifedipine) 
and benzothiazepines (BTZ; e.g. diltiazem). Each of these three types of drug has separate, 
but overlapping or allosterically linked, Ca2+ channel–binding sites on the IIIS6 and IVS6 
binding motifs (Fig. 5). 
The cardiovascular activities of these drugs as antihypertensive, antianginal and selective 
antiarrhythmic agents are due to their action on one particular calcium mobilization process: 
calcium entry through an L-type voltage-gated calcium channel (Triggle 2007). Many studies 
have demonstrated that in accord with their chemical heterogeneity these agents interact at 
discrete receptor sites associated with a major subunit of the channel Fig. 6 (Triggle 2007).  
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Figure 6. Ca2+ channel antagonist interactions at the L-type voltage-gated calcium 
channel 
In this schematic representation the three major structural classes of drug are shown 
interacting at separate but allosterically linked receptor sites. The drugs depicted in the circle 
are second-generation 1,4-dihydropyridines and include the widely prescribed amlodipine 
(Norvasc™). *Figure from Triggle (2007) 
 
1.4 Use-dependent block 
The normal operation of voltage-gated calcium channels involves conformational changes 
large enough to switch between states with completely open or completely closed water-filled 
pores. These switches between the gating states (resting, open, inactivated) typically occurs 
on a millisecond time scale in response to changes in membrane voltage and are often 
accompanied by dramatic changes in drug binding affinity. 
A use-dependent pattern is described where peak ICa is progressively reduced by a train of 
depolarizing test pulses since inhibition increases as channels are “used” by cycling through 
various gating states during the action potentials. The more frequently the Ca2+ channel 
opens, the better is the penetration of the drug to the binding site (see  Hering et al. 1997 for 
PAA action). Since then, single amino acids have been identified as inactivation determinants 
in motifs IIIS6, IVS6, and IVS5, with some of them also serving as high-affinity 
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determinants for the DHP receptor site (Benitah et al. 2002; Hering et al. 1998; Motoike et al. 
1999), BTZ binding site (Hockerman et al. 2000) and PAA binding site (Hering et al., 1997; 
Hockerman et al., 1995; Hockerman et al., 1997b). 
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2.1 INTRODUCTION 
 
L-type calcium channels belong to the high-voltage activated channel family (isoforms 
CaV1.1, CaV1.2, CaV1.3 and CaV1.4) and display a high sensitivity to calcium channel 
blockers (or Ca2+ antagonists) (Catterall et al., 2005). CaV1.2 participates in excitation-
contraction coupling in cardiac and smooth muscle, action potential propagation in sinoatrial 
and atrioventricular node, synaptic plasticity and hormone secretion and other processes 
(Striessnig et al., 1999; Catterall et al., 2000, Schulla et al., 2003, Sinnegger-Brauns et al., 
2004). Calcium antagonists are widely used to treat cardiovascular diseases such as 
hypertension, angina pectoris and arrhythmias (Triggle, 2007, Striessnig et al., 1999). They 
are a chemically heterogeneous group of drugs that exert their therapeutic effects by 
inhibiting voltage-gated L-type Ca2+ channels. The prototypical agents of this group are 
diltiazem (Dil; a benzothiazepinone, BTZ), nifedipine (a 1,4-dihydropyridine, DHP) and 
verapamil (a phenylalkylamine, PAA). Single amino acids determining the sensitivity of L-
type channels for calcium antagonists have been identified by mutational analysis and 
functional studies (Hering et al., 1996, Kraus et al., 1998, Striessnig et al, 1998, Berjukow et 
al., 1999 Hockerman et al., 2000, Dilmac et al., 2003).  
The binding sites for PAA and diltiazem share common amino acid residues but it is assumed 
that the two drug classes access their binding pockets from different sides of the membrane. 
There is clear evidence from studies with quaternary PAA analogues applied via the patch 
pipette that this class of CaV1.2 inhibitors interacts with an intracellular located binding site 
(Hescheler et al., 1982; Berjukov et al., 1996). Thus it is widely believed that tertiary PAAs 
penetrate the membrane and block CaV1.2 from the cytosolic side of the membrane in their 
protonated form in a use-dependent manner. CaV1.2 inhibition by diltiazem is also use-
dependent (Lee and Tsien, 1983; Uehara and Hume, 1985; Smirnov and Aaronson, 1998). 
Variation of external and internal pH revealed that diltiazem inhibits L-type channels in its 
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charged and neutral forms (Smirnov and Aaronson, 1998). Studies with a structurally related 
benzothiazepine (SQ32,428) suggested, however, an extracellular location of the diltiazem 
binding site (Hering et al., 1993). The latter finding is in apparent contradiction with 
mutational studies indicating that crucial diltiazem binding determinants overlap with 
determinants of PAA sensitivity located deeply in the channel pore (Hering et al., 1996; 
Kraus et al., 1998; Burjokow et al., 1999; Hockerman et al., 2000; Dilmac et al., 2003). 
Tikhonov and Zhorov (2008) pointed out that the potential BTZ binding determinants are 
located in the inner pore of Cav1.2 while some quaternary BTZ block the channel when 
applied externally rather than internally. The authors proposed a molecular model explaining 
the interaction with key amino acids of the putative binding pocket that were identified in 
functional studies. Tikhonov and Zhorov (2008) suggest that drug access occurs via the III/IV 
domain interface from the outside of the membrane. 
However, to date no study has systematically examined the extracellular and intracellular 
action of the therapeutically used diltiazem on CaV1.2. Therefore we synthesised the 
quaternary derivative of d-cis-diltiazem, qDil, and explored its effects when applied from 
outside or inside (via the patch pipette) of the cell membrane. Our data on wild-type and 
mutant CaV1.2 clearly demonstrate “use-dependent” intracellular access of qDil to the 
diltiazem binding pocket in CaV1.2.  
 
2.2 METHODS 
2.2.1 General Experimental Methods  
All chemicals obtained from commercial suppliers were used as received and were of 
analytical grade. Melting points were determined on a Kofler hot stage apparatus and are 
uncorrected. The 1H- and 13C-NMR spectra were recorded on a Bruker Avance DPx200 (200 
and 50 MHz).  
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2.2.2 Synthesis of quaternary Diltiazem 
To a solution of the free base of 0,829g (2 mmol) Diltiazem in 2 ml dichloromethane 0,568g 
(4 mmol) of iodomethane were added at room temperature. After 48h the reaction mixture 
was concentrated to dryness. The crude product of qDil was obtained and recrystallized from 
isopropanol to yield 0,807g (97 %) of qDil.  
The analysis of this material gave the following results: Mp 178-181°C; 1H-NMR (D2O): δ 
7.68 -7.64 (m, 3H), δ 7.38-7.26 (m, 3H), δ 6.89 (JA,B=8.58 Hz, 2H), δ 5.04 (q, 2H), δ 4.13-
4.08 (m, 1H), δ 3.96-3.83 (m, 2H), δ 3.72 (s, 4H), δ 3.42-3.38 (m, 1H), δ 3.09 (s, 9H), δ 1.80 
(s, 3H); 13C-NMR (D2O): δ 170.29, δ 169.10, δ 160.28, δ 144.35, δ 136.24, δ 132.83, δ 
131.02, δ 128.92, δ 127.65, δ 126.32, δ 125.63, δ 114.36, δ 71.85, δ 63.47, δ 55.74, δ 54.61, δ 
50.10, δ 44.54, δ 20,89.  
2.2.3 Purity of qDil 
The purity of qDil was confirmed by HPLC and was 98%. The analysis was performed using 
a Jasco UV-1575 Chromatograph. The stationary phase was a 5µm RP-18e Lichrospher 
Merck column (250mm x 4mm). As a mobile phase, ammonium acetate pH 6.0 + 0,5% 
DEA/CAN (50/50) was used.  
2.2.4 Cell Culture and Transient Transfection 
Human embryonic kidney tsA-201 cells were grown at 5% CO2 and 37°C to 80% confluence 
in Dulbecco’s modified Eagle’s medium/F-12 supplemented with 10% (v/v) fetal calf serum 
and 100 units/ml of penicillin and streptomycin. Cells were split using trypsin/EDTA and 
plated on 35-mm Petri dishes (Falcon) at 30-50% confluence 16 h before transfection. 
Subsequently, tsA-201 cells were co-transfected with cDNAs encoding wild-type 
(GenBankTM accession number X15539) or mutant CaV1.2 α1-subunits (I1150A, I1153A, 
I1156A, M1160A, F1164A, V1165A, I1460A, I1464A, Y1463F, F1117G, E1118Q, E1419Q; 
Hockermann et al., 2000) with auxiliary β2a, α2δ subunits (Ellis et al., 1998). The transfection 
 45 
of tsA-201 cells was performed using the FuGENE 6 transfection reagent (Roche Applied 
Science) following standard protocols. 
2.2.5 Ionic Current Recordings and Data Acquisition 
Barium currents (IBa) through voltage-gated Ca2+ channels were recorded at 22-25°C using 
the whole cell patch-clamp configration (Hamill et al., 1981) by Axopatch 200A patch clamp 
amplifier (Axon Instruments) 36-48 h after transfection.The extracellular bath solution 
contained 20 mM BaCl2, 1 mM MgCl2, 10 mM HEPES, and 140 mM choline-Cl, titrated to pH 
7.4 with methanesulfonic acid. The borosilicate glass patch pipettes (HARVARD 
APPARATUS) with resistances of 1–4 megohms were pulled and polished using a DMZ 
universal puller (Zeiss instruments, Germany), and were filled with pipette solution 
containing 145 mM CsCl, 3 mM MgCl2, 10 mM HEPES, and 10 mM EGTA, titrated to pH 
7.25 with CsOH.  
Intracellular application was done via the patch pipettes and IBa were recorded 5 min after the 
whole cell configuration was established. To ensure that the internal drug concentration 
reached steady state, use-dependent block was monitored after different time intervals. An 
approximation of the time for intracellular perfusion (Mathias et al., 1990) predicts that under 
our experimental conditions, an equilibrium between the pipette concentration of qDil and the 
intracellular solution should be reached within about 10 s.  
For extracellular application, the drug was applied to cells under voltage clamp using a 
microminifold perfusion system (ALA scientific Instruments, Westbury, NY). IBa were 
recorded by applying repetitive pulses after a 5 min equilibration period in drug-containing 
solution. Use-dependent Ca2+ channel block was estimated as peak IBa inhibition during a 
train of short (100 ms) test pulses from -80 mV at a frequency of 0.2 Hz. The dose-response 
curves of IBa inhibition were fitted using the Hill equation, ,
,
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where IC50 is the concentration at which IBa inhibition is half-maximal, C is the applied drug 
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concentration, B represents a non-blocked current and A the blocked current fraction (both in 
percent). Channel block levels observed in the presence of drug were corrected by subtracting 
the mean steady state inhibition (after 20 pulses, see Table 1) in controls. All data were 
digitized using a DIGIDATA 1200 interface (Axon Instruments), smoothed by means of a 
four-pole Bessel filter, and stored on computer hard disc. Leak currents were subtracted 
digitally using average values of scaled leakage currents elicited by a 10 mV hyperpolarizing 
pulse. Series resistance and offset voltage were routinely compensated. The pClamp software 
package (version 7.0 Axon Instruments, Inc.) was used for data acquisition and preliminary 
analysis.  
The voltage-dependence of activation was determined from current-voltage (I-V) curves in 
the absence and presence of drug. The curves were fitted according to the following modified 
Boltzmann term:  
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where Vrev, extrapolated reversal potential; V, membrane potential; I, peak current; Gmax, 
maximum membrane conductance; V0.5, act’ voltage for half-maximal activation; and kact, 
slope factor.  
The voltage-dependence of IBa inactivation (inactivation curve) in the presence and absence 
of drug was measured using a multi-step protocol (see Hohaus et al. 2005). In order to avoid 
accumulation of channel block, the pulse sequence was applied every 2 minutes from a 
holding potential of -80 mV. Inactivation curves were drawn according to a Boltzmann 
equation:  
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where V, membrane potential; V0.5, inact, midpoint voltage; k inact, slope factor and Iss, fraction 
of non-inactivating current.  
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Recovery from block was monitored by applying 6 short (20 ms) test pulses after the 
conditioning train. Application of the monitoring pulses in the presence of 300 µM of the 
used drugs did not induce measurable channel inhibition.  
Analysis and curve fitting was done with Microcal Origin 7.0. Data are given as Mean±S.E. 
Statistical significance was assessed using the Student’s unpaired t-test.  
 
2.3 RESULTS 
To clarify the interaction of diltiazem with either an extra- or intracellular binding site on 
CaV1.2, the membrane-impermeable quaternary derivative of d-cis-diltiazem (qDil) was 
synthesized (see Methods). CaV1.2 composed of wild-type or mutant α1 subunits and 
auxiliary α2-δ and β2a subunits were expressed in tsA 201 cells. qDil was applied 
intracellularly via the patch pipette and extracellularly in the perfusion bath. 
 
2.3.1 Intracellular and extracellular effects of quaternary d-cis-diltiazem  
As shown in Fig. 1 A qDil blocks IBa in a “use dependent” manner when applied via the patch 
pipette. IBa inhibition was induced by applying a train of 100 ms test pulses from -80 to 20 
mV at a frequency of 0.2 Hz. Fig. 1 C, D illustrates the acceleration of the current decay 
(statically not significant)  
during the first pulse. Current traces from control cells and first pulse currents of a train with 
qDil in the pipette were normalized and averaged. The direct comparison of control IBa and 
IBa in drug was not possible under these conditions.  
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Fig. 1 Use-dependent block of CaV1.2 by intracellularly applied quaternary diltiazem.  
A, Use-dependent inhibition of wild-type channels measured in the absence or presence of 
50, 100, 300 or 500 µM quaternary diltiazem in the intracellular (pipette) solution. Data 
points are the mean from 4-6 experiments.  
B, The IC50 values (d-cis-diltiazem: 95±5 µM (Hill slope nH=1.6±0.4) and qDil: 85±9 µM 
(nH=1.3±0.2)) were obtained by fitting the data points to the Hill equation (as described in 
“Methods” section). Channel block was estimated as peak IBa inhibition during trains of 20 
pulses (0.2 Hz, 100 ms) applied from a holding potential of -80 mV to +20 mV in control 
(Table 1) and in presence of quaternary diltiazem.  
C, Superimposed IBa during a train of 20 pulses with 300 µM quaternary diltiazem in pipette. 
D, Acceleration of current decay during the first pulse in train. Current traces were 
normalized and averaged. The mean peak current densities were -14.7 ± 0.9 (control) and -
13.8 ± 0.9 pA/pF (first pulse current after 3 minutes 300 µM qDil in the pipette). Bar graphs 
indicate remaining current at the end of the first pulse. 
 49 
 
Table 1 Peak current decay in the absence of drug after 20 pulses (100 ms) at 0.2 Hz 
Mutation Control inhibition, % 
WT 5.9±3.0 
I1150A 3.6±1.5 
I1153A 9.9±2.1 
I1156A 9.3±1.8 
M1160A 14.8±1.6 
F1164A 10.1±3.3 
V1165A 0.7±1.8 
I1460A 10.6±0.9 
Y1463F 0.9±1.2 
M1464A 0.7±3.0 
F1117G 9.5±1.2 
E1118Q 9.2±1.8 
E1419Q 3.6±4.8 
 
 
In order to evaluate potential resting state inhibition by qDil from the intracellular side we 
compared the peak current densities in control and after 3 minutes intracellular application of 
qDil (300 µM). The mean peak current densities of -14.7 ± 0.9 (control) and -13.8 ± 0.9 
pA/pF (calculated from first pulse IBa with 300 µM qDil in the pipette) suggest that qDil 
when applied from the intracellular side of the membrane induces only non significant resting 
state inhibition. We can not exclude that the reduced peak current density reflects open 
channel inhibition developing during the rising phase of current. 
The kinetics of peak current inhibition during pulse trains and the final steady state values 
were dependent on qDil concentration. The steady state values plotted versus the applied drug 
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concentrations are shown in Fig. 1 B. The IC50 values for IBa inhibition of wild-type CaV1.2 
by qDil and Dil were 95±5 µM and 85±9 µM respectively (Fig. 1 B). 
Extracellular application of 300 µM qDil induced 10±4% use-dependent IBa inhibition of 
wild-type CaV1.2 (Fig. 2 A,B) which was statistically not significantly different from the 
current decay during a pulse train in the absence of drug (6±3%). The same drug 
concentration induced 59±4% IBa inhibition when applied via the pipette indicating that qDil 
accesses its binding site on CaV1.2 from the intracellular side of the membrane (Fig. 1B).  
The tonic block of IBa (current inhibition after 3 min in drug at rest) induced by 100 and 300 
µM Dil and qDil is shown in Fig. 2 D. Neither 100 nor 300 µM of qDil induced substantial 
IBa inhibition (12±2% and 16±2% respectively). This block was not enhanced by repetitive 
pulsing. Extracellularly applied Dil induced larger tonic current inhibition than qDil which 
can be prescribed to channel inhibition by the neutral form of the drug (see Smirnov and 
Aaronson, 1998). 
 
 
Fig. 2 Extracellular quaternary diltiazem and intracellular SQ32,428 do not inhibit 
CaV1.2. 
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A. Superimposed IBa during a train of 20 pulses (same protocol as in Fig. 1) in the absence of 
drug, with 300 µM quaternary diltiazem in the bath solution and with 300 µM SQ32,428 in 
pipette. 
B, Structures of quaternary diltiazem and BTZ SQ32,428. 
C, Lack of significant IBa inhibition by extracellularly applied qDil (300 µM) and 
intracellularly applied SQ32,428 (300 µM). Peak current decay with 300 µM qDil in the 
pipette is shown for comparison as a broken line (data from Fig. 1A). Data points are the 
mean from 4-6 experiments.  
D, Bar graphs illustrate tonic IBa inhibition (block after 3 minutes in drug at rest at -80 mV) 
induced by 100 and 300 µM Dil, qDil and SQ32,428 applied extracellularly. 
 
Intracellularly applied 300 µM SQ 32,428 (a quaternary benzothiazepine, see also Hering et 
al., 1993) induce minor channel inhibition (Fig. 2 C). The structures of qDil and SQ 32,428 
are compared in Fig. 2 B. Externally applied SQ 32,428 (100 and 300 µM) inhibited IBa by 
23±2% (n=5) and 43±3% (n=5) in a non use-dependent manner (Fig. 2 D, see Hering et al., 
1993 for similar experiments on BC3H1 cells).  
In order to estimate potential tonic inhibition by qDil applied via the patch pipette we 
compared the currents in control (pipette does not contain qDil) with the first pulse IBa 
amplitude after a 3 minute equilibration with 300 µM qDil in the pipette. The estimated 
current densities of -14.7±0.9 pA/pF and -13.8 ±0.9 pA/pF suggest that qDil induces non 
significant resting state inhibition when applied from the intracellular side of the membrane. 
 
 
2.3.2 qDil interaction with the diltiazem binding site 
Six amino acid residues on segment IIIS6 and three residues on segment IVS6 (Fig. 3 A) of 
the CaV1.2 α1 subunit have been shown to affect channel inhibition by Dil (Hering et al., 
1996; Hockerman et al., 2000; Dilmac et al., 2003). To elucidate whether its quaternary 
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derivative interacts with the same binding pocket we first studied IBa inhibition in IIIS6 
mutants I1150A, I1153A, I1156A, M1160A, F1164A and V1165A by intracellularly applied 
qDil. Three mutants (I1150A, F1164A, V1165A) significantly reduced sensitivity for qDil 
(Fig. 3 B, C) which is in line with their strong effects on Dil sensitivity (Hockerman et al. 
2000). The other mutations induced moderate (not statistically significant) effects which 
might reflect the different experimental conditions. Rare pulsing every 20 sec (0.05 Hz) from 
-60 mV induces predominantly tonic block (Hockerman et al. 2000) while frequent pulsing 
every 5 sec (0.2 Hz) induces predominantly use-dependent block (present study). Mutations 
of the key determinants of Dil sensitivity in segment IVS6 (I1460A, Y1463F and M1464A, 
Hockerman et al. 2000) all significantly reduced qDil sensitivity (Fig. 3 D, E). To determine 
a possible interaction of qDil with potential binding sites in the selectivity filter we analyzed 
IBa inhibition of mutants F1117G, E1118Q and E1419Q. A moderate reduction in block 
compared to wild type was observed (Fig 3 F, G) which is in line with a study of Dilmac et 
al. (2003).  
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Fig. 3 Mutations of the putative Dil binding site affect IBa inhibition by intracellularly 
applied qDil. 
A, Amino acid sequence of the transmembrane segments IIIS6 and IVS6 of the CaV1.2 αı 
subunit. Putative diltiazem binding determinants are highlighted.  
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B, Peak current decay in mutants I1150A, I1153A, and V1165A channels induced by 300 µM 
quaternary diltiazem in the pipette solution (protocol as in Fig. 1).  
C, Remaining currents after 20 pulses in WT and the indicated IIIS6 mutants. Asterisks 
denote that the steady state block value for quaternary diltiazem of the indicated mutant 
channel is significantly different from that of WT (Student’s t test: *P < 0.05, **P < 0.01, #P 
= 0.057). 
D, Use-dependent inhibition of I460A and M1464A channels by 300 µM of qDil in the 
pipette solution.  
E, Remaining currents of WT CaV1.2 and the indicated IVS6 mutants. Asterisks indicate that 
the steady state block value for quaternary diltiazem of the indicated mutant channel is 
significantly different from that of WT (Student’s t test: *p < 0.05, **p < 0.01). 
F, Use-dependent inhibition of selectivity filter mutants F1117G, E1118Q and E1419Q by 
300 µM qDil in the pipette solution.  
G, Remaining currents after 20 pulses in WT and the indicated CaV1.2 mutants in 100 and 
300 µM qDil in the pipette. Asterisks indicate where there is a significant difference between 
the steady state block of the indicated mutant channel and the WT (Student’s t test: *p < 0.05, 
**p < 0.01, #p = 0.057). 
The broken lines in B, D and F represent peak current inhibition in wild type (taken from Fig. 
1 A). Channel block in C, E and G was estimated by subtracting “steady state” inhibition 
after 20 pulses in drug-free solution (Table 1) from channel block induced by 100µM or 
300µM of qDil. 
 
 
2.3.3 Modulation of channel gating by quaternary and tertiary diltiazem 
To obtain insights into the link between state-dependent inhibition and channel gating we 
measured the standard characteristics of channel gating in control and the presence of drug. 
The activation and inactivation curves are shown in Fig. 4. Neither Dil (extracellular 
application) nor qDil (intracellular application) affected the activation curve of CaV1.2 (Fig. 
4A, Table 2) and neither of them affected the kinetics of current activation and deactivation . 
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Fig. 4 Changes in channel gating induced by Dil and qDil.  
Steady-state activation (A) and inactivation (B) of WT in the absence (open circles) or 
presence of 300 µM qDil applied from intracellular side (filled circles) or 300 µM of Dil 
applied by bath perfusion (filled squares, see Table 2 for parameters of the Bolzmann 
distributions). 
 
Table 2 Effects of qDil and d-cis-diltiazem on voltage-dependent gating of CaV1.2 
Midpoints and slope factors of the activation and inactivation curves and remaining current 
after 1000-ms pulse (r1000) at 0 mV pulse (n=3÷6). 
WT V0.5,act , mV kact , mV V0.5,inact , mV kinact , mV r1000, % 
Control -6.4±0.7 5.6±0.6 -41.4±1.0 7.4±0.9 69±6 
300 µM qDil 
(intracellular) 
-6.3±0.7 5.3±0.7 -48.5±0.9 7.7±0.8 44±11 
300 µM Dil 
(extracellular) 
-8.2±0.8 6.2±0.7 -46.4±1.2 7.2±1.1 38±10 
 
 
In line with previous studies we observed a leftward shift of the inactivation curve by 300 
µM Dil (5.0±1.5 mV). Quaternary diltiazem applied at the same concentration from the 
intracellular side induced a very similar shift (7.1±1.3 mV) suggesting similar state-
dependency of both compounds (Fig. 4 B). 
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Fig. 5 Recovery of wild-type CaV1.2 from block by intracellularly applied qDil and 
extracellularly applied Dil.  
A-B, Recovery from block by 300µM intracellular quaternary (circles) or 300µM 
extracellular tertiary diltiazem (squares) at -80mV holding potentials. Block was elicited by a 
standard conditioning train of 20 pulses in the presence of and recovery monitored by 
applying short (20 ms) test pulses at different time after the train. The mean time constants of 
recovery from block by Dil and qDil were 32.3±5.2 (n=7) and 37.1±4.9 (n=9) respectively. 
Recovery from block by qDil and Dil was compared at a holding potential of -80 mV. Figure 
5 illustrates the very similar recovery from block by intracellular qDil and extracellularly 
applied Dil (τ(qDil)=37.1±4.9 s vs. τ(Dil)=32.3±5.2 s).  
 
 
2.4 DISCUSSION 
CaV1.2 displays a high sensitivity to calcium antagonists such as DHPs, PAAs and diltiazem 
(Striessnig et al., 1991, Hockerman et al., 1997, Catterall et al., 2005). Calcium antagonists 
are clinically used to treat hypertension and angina pectoris (Fleckenstein et al., 1980, 
Triggle, 2007) PAAs and diltiazem are also used as antiarrhythmics and block L-type 
(CaV1.2) channels more efficiently at higher frequencies (Lee and Tsien, 1983). 
Putative diltiazem binding determinants were identified on pore forming segments IIIS6 and 
IVS6 and the selectivity filter region (Hering et al., 1996; Kraus et al., 1998; Berjukov et al., 
1999; Hockerman et al., 2000; Dilmac et al., 2003). A modulating role of channel 
inactivation in block by diltiazem was revealed in studies with mutant and chimeric CaV1.2 
constructs (Berjukov et al., 1999; Dilmac et al., 2003; Motoike et al., 1999). Like PAAs, 
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diltiazem blocks CaV1.2 channels in a use-dependent manner (Hockerman et al., 2000; Lee 
and Tsien, 1983). The molecular mechanism of channel inhibition and the access path of 
diltiazem to its receptor site are, however, less understood. A quaternary BTZ (SQ32,428, 
Fig. 1D) was shown to block L-type channels in BC3H1 cells when applied from the 
extracellular side of the membrane in a non-use-dependent manner (Hering et al. 1993). 
Extracellular application of 100 and 300 µM of SQ32,428 on heterologously expressed 
CaV1.2 in the present study confirmed this observation. Tikhonov and Zhorov (2008) 
hypothesised that access of the “bulky BTZs” is unlikely to occur through the open activation 
gate from the intracellular side and proposed a “side walk” access of BTZ molecules from the 
extracellular side via the III/IV domain interface to their binding site in the pore. As shown in 
figure 1, qDil inhibited IBa predominantly when applied to the intracellular side of the 
membrane. The estimated tonic inhibition by intracellularly applied qDil was small (current 
density of -14.7 ± 0.9 pA/pF in control vs. –13.9 ± 1.1 pA/pF after first pulse in the presence 
of 300 µM qDil). Extracellular application (up to 300 µM) induced no use-dependent effect 
(Fig. 2 C) and only a low level of tonic current inhibition (Fig. 2 D). The more pronounced 
tonic IBa inhibition by Dil (Fig. 2 D) contributes to its concentration-inhibition relationship. 
This is evident from Fig. 1 B where stronger IBa inhibition by Dil was particularly evident at 
high drug concentrations (See Fig. 2 D).  
Our principle finding that intracellularly applied qDil accesses its binding site through the 
open activation gate is in line with data of Smirnov and Aaronson (1998) who suggested that 
use-dependent current inhibition is induced by the charged form of diltiazem from inside. 
Furthermore, intracellular channel inhibition by qDil was modulated by four IIIS6 and three 
IVS6 mutations that have previously been identified as putative diltiazem binding 
determinants. Selectivity filter mutations less efficiently prevented channel block which is in 
line with Dilmac et al. 2003.  
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Taken together these data support a scenario where intracellularly applied qDil and 
extracellularly applied Dil interact with the same or largely overlapping binding pockets in 
the channel pore (Fig. 3).  
Intracellular access of the permanently charged qDil to its binding site seems to occur in a 
very similar way as previously shown for quaternary PAAs. Quaternary PAAs approach their 
binding site on CaV1.2 from the intracellular face of the plasma membrane and repeated 
channel opening facilitates access of PAAs to the pore region which explains use-dependent 
block (Hescheler et al., 1982; Berjukov et al., 1996; Beyl et al. 2008). The access path of 
charged 1,4 DHPs occurs, however, via a pathway from the extracellular site of the 
membrane. Amlodipine in its ionised form and the permanently charged quaternary DHP 
derivative SDZ 207-180 were found to be ineffective when applied intracellularly, suggesting 
that the DHP receptor site is inaccessible from the intracellular surface while extracellular 
application of these compounds results in channel block indicating that these antagonists gain 
access to the receptor site via an extracellular pathway (Kass et al. 1991, see Hockerman et 
al. 1997 for review). It is tempting to speculate that DHPs reach their receptor determinants 
in the pore via the side walk access proposed by Thikhonov and Zhorov (2008). 
2.4.1 Similar state dependency of Cav1.2 inhibition by qDil and Dil 
 High affinity binding to open and inactivated channel states are important characteristics of 
use-dependent channel blockers. In order to analyse drug accesses via the intracellular 
channel mouth we have co-expressed the α1 subunit of Cav1.2 with the β2a subunit which is 
known to prolong the open state by minimising channel inactivation. As shown in Figs 1 C, D 
the absence of inactivation during short pulses did not prevent use-dependent channel block 
suggesting access of qDil to its binding site via the open gate. Block development was slow 
and equilibrated at 300 µM over 15 100 ms pulses (Fig. 1 A). Slow block development is also 
evident from the acceleration of the current decay with 300 µM qDil in the pipette (Fig. 1 D) 
and the non significant changes in the steady state activation curve (Fig. 4 A) (see also Lee 
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and Tsien, 1983). However, channel inhibition is modulated by inactivation as evident from 
the shifts of the availability curves in Fig. 4 B (see also Zhang et al. 2010). 
Accumulation of channel inhibition during a pulse train illustrated in Fig. 1 A depends on 
channel recovery between pulses. Recovery from use-dependent block by qDil and Dil was 
found to be very similar (Fig. 5, τ(qDil)=37.1±4.9 s vs. τ(Dil)=32.3±5.2 s). Similar recovery 
from block and similar apparent affinities (IC50(Dil)= 95±5µM and IC50(qDil) = 85±9µM) 
support the hypothesis that both compounds interact with identical or largely overlapping 
binding determinants in the channel pore. 
The differences in tonic block observed for Dil and qDil warrants further research. The 
negligible “intracellular tonic IBa inhibition” induced by intracellular qDil (current density of 
-14.7 ± 0.9 pA/pF in control vs. –13.9 ± 1.1 pA/pF after first pulse in the presence of 300 µM 
qDil) suggests that the charged form induces predominantly use-dependent block, while the 
neutral form may be responsible for tonic inhibition (see also Smirnov and Aaronson, 1998). 
Access of the neutral form of Dil to its binding determinants in the pore via the side walk 
access (Thikhonov and Zhorov, 2008) can not be excluded. 
 
2.5 Conclusions and outlook 
Data of the present study demonstrate intracellular access of quaternary (membrane-
impermeable) diltiazem and the interaction of qDil with determinants of the binding pocket 
previously identified for tertiary diltiazem (Hering et al., 1996; Hockerman et al., 2000; 
Dilmac et al., 2003). Quaternary diltiazem accesses its binding determinants via the inner 
channel mouth in a similar manner as was previously found with quaternary PAAs. Our data 
suggest that use-dependent block of CaV1.2 by diltiazem occurs predominantly via the open 
channel conformation.  
Our study also permits new insights into the structure-activity relationship of this 
therapeutically important drug. A structurally related BTZ (SQ32,428) has no effect when 
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applied from the cytosolic side (Fig.2 A, C, see also Hering et al., 1993). Compared to 
SQ32,428 the C5 of qDil is replaced by a sulfur atom and the trifluoromethyl group in 
position C6 is substituted by a hydrogen atom. Additionally, the methyl group of SQ32, 428 
in position C3 is replaced by an acetoxy group (Fig. 2 B). Any of these apparently small 
structural differences may be essential for interaction of d-cis-diltiazem with its intracellular 
or extracellular accessible binding sites. Thikhonov and Zhorov, 2008 proposed an interesting 
concept how the functional groups of BTZ may interact with individual amino acid residues 
in the pore. Derivatives of quaternary diltiazem (with individually replaced moieties) may 
thus represent interesting tools for investigating the molecular basis of use-dependent drug 
interactions with intracellular accessible binding determinants. 
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3 CHAPTER III 
T1143 ESSENTIAL FOR CAV1.2 INHIBITION BY DILTIAZEM: 
REFINED DRUG BINDING MODEL  
 
MS by Shabbier et al. in preparation 
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3.1 INTRODUCTION 
Calcium channel inhibitors are widely used as cardiovascular therapeutics and serve as important tools 
to probe the structure and function of this ion channel family (Beyl et al. 2007). L-type calcium 
channels are inhibited by 1,4-dihydropyridines (DHPs), phenylalkylamines (PAAs) and 
benzothiazepines (BTZ). Diltiazem (Dil) chemically belongs to the BTZ and is used to treat 
hypertension, angina pectoris, arrhythmias and other cardiovascular disease (Triggle 2003, 2006, 
2007; Zhang et al. 2003). Like PAAs Dil inhibits L-type channels in a state-dependent manner (Lee 
and Tsien 1983). Resting state block is evident from current inhibition in the absence of channel 
activation or at low pulse frequency (Berjukow et al. 1999). High-affinity interaction of Dil with open 
and inactivated channels is shown by channel block developing during repetitive pulsing (“use-
dependence”) and from a drug-induced shift of the steady-state inactivation curve (Lee and Tsien 
1983), (Uehara and Hume 1985). Also, L-type channels are more efficiently inhibited by Dil when 
Ca2+ rather than Ba2+ is used as a charge carrier (Lee and Tsien 1983). 
Experiments with the photoreactive diltiazem-like antagonist [3H]benziazem indicated that key 
binding determinants of Dil on L-type Ca2+ channels are located on transmembrane segments IIIS6 
and IVS6 of the pore-forming α1C-subunit (Kraus et al. 1996). This was later confirmed in systematic 
mutation studies where six residues in segment IIIS6 (I1150, I1153, I1156, M1160, F1164 and V1165) 
and three residues in segment IVS6 (I1460, Y1463 and M1464) were identified as determinants of Dil 
sensitivity (Dilmac et al. 2003; Hering et al. 1996; Hockerman et al. 2000; Hockerman et al. 1997; 
Hockerman et al. 1995; Kraus et al. 1998). Dilmac et al. (2003) concluded that three (Hockerman et al. 
1995) residues in the selectivity filter region (E1118, E1419, and F1117) modulate channel inhibition 
with Ca2+ as charge carrier (Dilmac et al. 2003). Removal of inactivation by point mutations in S6 
segments can diminish channel block by Dil (Berjukow et al. 1999; Hering et al. 1997; Kraus et al. 
1998; Motoike et al. 1999). This “allosteric modulation” complicates the identification of the putative 
drug binding site (Hering 2002). The access path of BTZ to their binding site in Cav1.2 is still 
controversial (see (Tikhonov and Zhorov 2008). We have, however, recently shown that the 
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quaternary (membrane-impermeable) diltiazem (qDil) accesses its binding pocket via an intracellular 
pathway in a use-dependent manner (Shabbir et al.) 
Several homology models were recently developed for the open pore of Cav1.2, where key 
determinants of calcium channel blockers are located (Bruhova et al. 2008; Bruhova and Zhorov; 
Stary et al. 2008; Tikhonov and Zhorov 2008). 
By docking a BTZ (SQ32910) into a homology model of transmembrane segments S5, S6 and P-loops 
of the four domains of α1C, Tikhonov and Zhorov (2008) proposed the first three-dimensional model 
of the BTZ binding site. The Tikhonov-Zhorov model integrates the results of previous mutational 
studies and enabled insights into the putative binding pocket for Dil.  
Structure-activity relationships of BTZs reveal that (Das et al. 1992; Floyd et al. 1992; Kimball et al. 
1992) the blocking potency is affected by the configurations of the chiral centers and modification of 
the substituents of the BTZ rings.  
In line with mutational studies, the Tikhonov-Zhorov model integrates Y1463 as possible H-bonding 
site. Other potential H-bond interactions in vicinity of the BTZ binding pocket were discussed, but not 
included in the model (Tikhonov and Zhorov 2008).  
COMFA models suggest, however, that BTZ interact with their receptor through a negative charge 
site, two hydrogen-bonding sites, and three hydrophobic regions (Corelli et al. 1997) et al, 1997). 
In the present study, we first analyzed potential H-bond interactions of Dil in a homology model of the 
open Cav1.2 pore structure. This process led to identification of residues T1067, S1142 and T1143 as 
candidates for H-bond contacts. These residues were then individually mutated to alanine in order to 
study the effects on channel inhibition by Dil. In our study we made use of Dil and its quaternary 
derivative interacting with the intracellular accessible binding site (Shabbir et al.). T1143 was 
identified as a novel strong determinant of Dil sensitivity. We propose a refined model of the Dil 
binding site on CaV1.2. 
 
3.2 EXPERIMENTAL PROCEDURES 
Mutagenesis- The CaV1.2 α1-subunit coding sequence (GenBank™X15539) in-frame 3' to the coding 
region of a modified green fluorescent protein (GFP) was kindly donated by Dr. M. Grabner (Grabner 
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et al. 1998). Substitutions in segment IIIS5, IIISF of the CaV1.2 α1-subunit were introduced using the 
QuikChange® Lightning Site-Directed Mutagenesis Kit (Stratagene) with mutagenic primers according 
to the manufacturer’s instructions. Mutations were introduced in segment IIIS5 in position T1067A 
and in the selectivity filter of domain III in positions S1142A and T1143A. All constructs were 
checked by restriction site mapping and sequencing. 
Cell culture and transient transfection- Human embryonic kidney tsA-201 cells were grown at 5% 
CO2 and 37°C to 80% confluence in Dulbecco's modified Eagle's/F-12 medium supplemented with 
10% (v/v) foetal-calf serum and 100 units/ml penicillin/streptomycin. Cells were split using 
trypsin/EDTA and plated on 35-mm Petri dishes (Falcon) at 30–50% confluence 16 h before 
transfection. Subsequently tsA-201 cells were co-transfected with cDNAs encoding wild-type 
(GenBankTM accession number X15539) or mutant CaV1.2 α1-subunits (T1067A, S1142A, 
T1143A), with auxiliary β2a- and α2δ-subunits (Ellis et al. 1988). The transfection of tsA-201 cells 
was performed using the FuGENE 6 transfection reagent (Roche Applied Science) following standard 
protocols. 
Ionic current recordings and data acquisition— Barium currents (IBa) through voltage-gated Ca2+ 
channels were recorded at 22–25°C using the whole-cell patch clamp configuration (Hamill et al. 
1981) by Axopatch 200A patch clamp amplifier (Axon Instruments) 36–48 h after transfection. The 
extracellular bath solution contained 20 mM BaCl2, 1 mM MgCl2, 10 mM HEPES, and 140 mM 
choline-Cl, titrated to pH 7.4 with methanesulfonic acid. The borosilicate glass patch pipettes (Harvard 
Apparatus, Holliston, MA, USA) with resistances of 1–4 MΩ  were pulled and polished using a DMZ 
universal puller (Zeitz Instruments, Martinsried, Germany), and were filled with pipette solution 
containing 145 mM CsCl, 3mM MgCl2, 10 mM HEPES, and 10 mM EGTA, titrated to pH 7.25 with 
CsOH. Quaternary diltiazem was dissolved for intracellular application in the internal (pipette) 
solution and for extracellular application in bath saline. Intracellular application was done via the 
patch pipettes and IBa were recorded 5 min after the whole cell configuration was established. To 
assure that that the internal drug concentration reached steady state, use-dependent block was 
monitored after different time intervals. An approximation of the time for intracellular perfusion 
(Mathias et al. 1990) predicts that under our experimental conditions, an equilibrium between the 
pipette concentration of (+)qDiltiazem and the intracellular solution should be reached within about 
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10s. For extracellular application, the drug was applied to cells under voltage clamp using a 
microminifold perfusion system (ALA scientific Instruments Westbury, NY) and IBa were recorded 
after a 5-min equilibration period. Use-dependent Ca2+ channel block was estimated as peak IBa 
inhibition during short (100 ms) test pulses from –80 mV at a frequency of 0.2 Hz. The dose-response 
curves of IBa inhibition were fitted using the Hill equation, IBa, drug/IBa, control (in %) = (100 – 
A)/(1+(C/IC50)nH) + B, where IC50 is the concentration at which IBa inhibition is half-maximal, A is 
the applied drug concentration. IBa-unblock from use-dependent inhibition by qDiltiazem was studied 
by applying a 20-ms test pulse at various time intervals after the last pulse of the train.  
All data were digitized using a DIGIDATA 1200 interface (Axon Instruments), smoothed by 
means of a four-pole Bessel filter, and stored on computer hard disc. Leak currents were 
subtracted digitally using average values of scaled leakage currents elicited by a 10-mV 
hyperpolarizing pulse. Series resistance and offset voltage were routinely compensated for. 
The pClamp software package (version 7.0 Axon Instruments, Inc.) was used for data 
acquisition and preliminary analysis. Microcal Origin 7.0 was used for analysis and curve 
fitting.  
Molecular modelling- The structure of the open Cav1.2 pore model was taken from Stary et 
al., 2008. Refinement of the binding pocket, the P-helix and the selectivity filter region of 
domain III are described in detail in the results section. 
The structure of Dil was downloaded from the pubchem database and geometry optimized with the 
Hartee-Fock 3-21G basis set implemented in Gaussian03 (Frisch et al, 2003).  
Initially the drug was placed manually into the BTZ binding site, and the OPLS 2001 force field was 
used to energy-minimize the complex. Subsequent docking was performed with the program Gold 
4.0.1 using the Gold scoring function. Side-chains of residues M1160, F1164 and Y1463 were taken 
from rotameric libraries (Cite GOLD). 150,000 operations of the GOLD genetic algorithm were used 
to dock diltiazem into the Cav1.2 model. The best-ranked 10 poses of each docking run were used for 
visual analysis of binding.  
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3.3 RESULTS 
3.3.1 Model predictions of potential H-bond interactions with Dil. 
In order to identify amino acids capable of forming H-bonds with Dil we made use of our previously 
published homology model of the Cav1.2 pore in open conformation (Stary et al. 2008). Visual 
inspection of the 3D coordinates  suggested three polar candidate residues for H-bond formation 
(T1067 in IIIS5, S1142, and T1143 in the IIISF) in close proximity (~ 6 Å) to known binding residues 
(Fig. 1). 
 
 
Fig 1.Diltiazem binding site in Cav1.2 homology model 
Known binding residues in domains III and IVS6 are shown as orange or red sticks. A cluster of 
putative candidate residues for H-bond formation from helix IIIS5 and the selectivity filter of domain 
III are shown as green sticks.  
 
 
These amino acids were subsequently mutated to alanine and their contributions to channel inhibition 
by Dil or qDil analysed in functional studies.  
 
3.3.2 Use-dependent block of T1143A. 
Barium (Ba2+) currents through Cav1.2 were measured with the patch clamp technique in tsA-201 
cells expressing α1C and the auxiliary β2a and α2-δ1-subunits. Using the quaternary derivative (qDil) 
we have recently shown that Dil accesses its binding site from the intracellular side (Shabbier et al., 
2010). To exclude complications by potential extracellular effects, we applied qDil via the patch 
pipette and analyzed current inhibition in candidate mutants T1067A (IIIS5), S1142A, T1143A 
(IIISF). IBa inhibition was first induced with 100 and 300µM qDil applied to the pipette using pulse  
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Fig 2.Use-dependent block of CaV1.2 by intracellularly applied quaternary diltiazem. 
A, representative traces of IBacurrent through WT Cav1.2 and T1143A channels in the 
presence of 300µM qDil. B, use-dependent inhibition of wild-type and mutant channels was 
measured in the absence or presence of 100µM and 300µM qDil in the pipette (intracellular) 
solution. Channel block was estimated as peak IBa inhibition during trains of 20 pulses (0.2 
Hz, 100 ms) applied from a holding potential of -80 mV to +20 mV. C, Use-dependent block 
accumulated after 20 pulses in WT and indicated mutants. Channel block was estimated as the 
difference between normalized current in presence of 100/300µM qDil and in absence of 
drug. Asterisks denote that the block value for quaternary diltiazem of the indicated mutant 
channel is significantly different from that of WT (Student's t test: *P< 0.05) 
 
 
trains applied at a frequency of 0.2 Hz. As shown in Fig. 2C, only T1143A significantly 
reduced sensitivity to qDil (Fig. 2 B) compared to wild type.  
Similar findings were made with tertiary diltiazem (Dil). As shown in Figs. 4 and 8, T1143A 
prevented use-dependent IBa inhibition. Mutating the other candidate residues to alanine 
(T1067A and S1142A) did not change channel inhibition by 300 µM qDil (Fig. 2C). 
 
3.3.3 Use-dependent block of other T1143 mutants. 
Next we replaced T1143 with different residues to determine how the physicochemical 
properties of the amino acid side chain affected channel block. All mutants displayed reduced 
current inhibition  
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Fig 3. Effect of other T1143 mutations on Cav1.2 inhibition by qDil  
A, use-dependent inhibition of T1143 mutant was measured in the absence or presence of 300 
µM qDil in the pipette solution. Channel block was estimated as peak IBa inhibition during 
trains of 20 pulses (0.2 Hz, 100 ms) applied from a holding potential of –80 mV to +20 mV. 
B, Use-dependent block accumulated after 20 pulses in WT and indicated mutants. Channel 
block was estimated as the difference between normalized current in presence of 100/300µM 
qDil and in absence of drug. 
 
Table 1. Peak current decay in the presence of qDil after 20 pulses (100 ms) at 0.2 Hz 
Use-dependent block, % 
Mutation 100 µMqDil 300 µMqDil 
WT 34.2 ± 5.5 53.3 ± 4.0 
T1143E 9.3 ± 2.3 30.3 ± 4.5 
T1143V 9.0 ± 3.3 29.8 ± 1.1 
T1143C 11.7 ± 2.3 28.3 ± 2.3 
T1143N 0.7 ± 3.9 23.2 ± 1.6 
T1143S 4.7 ± 2.9 19.7 ± 2.9 
T1143Y 1.3 ± 2.8 11.7 ± 3.0 
T1143A 5.8 ± 3.9 11.7 ± 3.9 
T1143L 2.5 ± 1.01 10.7 ± 3.3 
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compared to wild type. However, as shown in Fig. 3 B, mutants T1143E/V/C/N/S were more 
efficiently blocked than constructs T1143A/Y/L. (See table 1 for block by values of, 100 and 
300µM qDil block). As shown in Figs. 4 and 8, T1143A prevented use-dependent IBa 
inhibition of Diltiazem. Mutating the other candidate residues to alanine (T1067A and 
S1142A) did not change channel inhibition by 300 µM qDil (Fig. 2C). 
 
 
Fig 4. T1143A abolishes block by Diltiazem 
A, representative traces of IBacurrent through WT and T1143A channels in the presence of 
extracellularly applied 50 µM Dil. B, use-dependent inhibition of wild-type and T1143A 
channelswas measured in the absence or presence of 50 µM Diltiazem in the bath. Channel 
block was estimated as peak IBa inhibition during trains of 20 pulses (0.2 Hz, 100 ms) applied 
from a holding potential of –80 mV to +20 mV.  
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3.3.4 Mutation T1143A does not affect channel gating. 
Changes in channel gating may have allosteric effects on Cav1.2 inhibition by calcium 
antagonists (Hering, 2002). We therefore investigated possible changes in channel gating by 
measuring the activation and inactivation curves with the mutant T1143A. T1143A does not 
shift the activation (∆Vact = –5.7±0.7 mV) and inactivation curve (–43.7±0.7) compared to 
WT (∆Vact = –6.5±0.7 and inactivation –42.8±0.8mV. A family of inward Ba2+ currents and 
the corresponding current-voltage (I-V) curve of mutant T1143A are shown in Fig. 5 and 
Table 3. 
 
 
Fig 5. Kinetics of IBa through wild-type Cav1.2 and T1143A. 
A, representative traces of IBacurrent through WT and T1143A channels. 
B, normalized current-voltage relationships of the wild-type (n = 9, open circles) and T1143A 
(n = 11) channels. Potentials of half-maximal activation (V0.5,act) are –6.5 ± 0.7 mV and  -
5.7 ± 0.7 mV, for wild-type, and T1143A mutant channels, respectively. C, average voltage 
dependencies of steady-state inactivation for wild-type (n = 4, open circles) and T1143A (n = 
4, filled squares) mutant channels. Solid lines represent fits to Boltzmann functions. Potentials 
of half-maximal inactivation (V0.5, inact) are –42.8, -± 0.8 mV, -43.7 ± 0.7 mV, for wild-type 
and T1143A and mutant channels respectively.  
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3.3.5 Frequency dependence of block. 
To determine whether T1143A is accessible for qDil at high frequency, we tested Cav1.2 
inhibition during 1 Hz pulse trains. Fig. 6 illustrates the corresponding use-dependent block. 
The strong reduction of IBa inhibition by T1143A was confirmed with 50µM of tertiary Dil 
that was applied by bath perfusion (Figs. 4 and 8).  
 
Fig 6. T1143A diminishes qDIl block at 1Hz frequency 
Use-dependent inhibition of wild-type and T1143A mutant channels was measured in the 
absence (open symbols) or presence of 300 µm qDil (closed symbols) in the pipette 
(intracellular) solution.  
 
 
 
3.3.6 Putative Diltiazem binding mode—comparison with SAR studies and COMFA 
model. 
Docking was used to investigate putative interactions of T1143 with diltiazem. Initially, the 
drug was placed manually into the cavity followed by stepwise energy minimizations with the 
OPLS forcefield. Guided by the size of the drug molecule, the P-helix and the selectivity filter 
region of domain III were slightly adjusted to accommodate Dil. This drug-guided model 
refinement resulted in an upward shift of the IIIP domain of approximately 1.5 Å. These 
structural changes increased the numbers of favorable hydrogen bonds in domain III. New 
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hydrogen bonds are formed between Q1070 (IIIS5) and S1142 and T1143 (IIISF). The 
hydroxyl group of Y1152 (IIIS6) binds to the hydroxyl group of S1142 (IIISF) and the 
backbone carbonyl oxygen of V1141 (C-terminus of III-P helix). The hydroxyl group of 
Y1463 (IVS6) binds to the hydroxyl group of T1066 (IIIS5) and backbone oxygen atom of 
T1067 (see supplementary Fig. 2). The stability of this drug-refined model was tested in a 40-
ns MD simulation (see supplementary information). This model was subsequently used to 
perform docking simulations. The program GOLD was employed to generate binding poses 
of diltiazem in the open Cav1.2 cavity utilizing its scoring function. Fig. 7A shows the 
binding mode of diltiazem that is in best agreement with experimental data. Hydrogen bonds 
are predicted between diltiazem and the hydroxyl group of T1143 from the selectivity filter of 
domain III. The polycyclic core of the drug is tightly packed with hydrophobic residues 
M1160 and F1164. Additional hydrophobic interactions are predicted with residues I1156 and 
A1157. The location of the negative charge, which does not directly interact with the 
glutamates from the EEEE locus, is marked with an asterisk. The positively charged nitrogen 
is oriented toward the base of the selectivity filter. Our model suggests that M1464 does not 
directly interact with diltiazem, as this residue is located within 6 Å of the drug. M1464 
could, however, provide weak hydrophobic interactions (depending on the docking pose). Fig. 
7B illustrates the agreement between the features suggested by the docking pose and the 
QSAR study by Corelli et al, 1997. Hydrophobic residues I1150 and I1153 are not within 6 Å 
of the drug. This observation agrees with the Tikhonov-Zhorov model, where allosteric 
effects for some BTZ sensitive residues, not directly interacting with drugs in their model, 
have been proposed.  
To further analyse this, all 100 docking poses in the open conformation were considered. 
However, in none of them did all ten experimentally determined binding determinants directly 
interact with diltiazem at the same time.   
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             A                                                               B 
 
Fig 7. Putative Binding mode of diltiazem in the open Cav1.2 channel 
A, Known binding residues are shown as orange (IIIS6) and red (IVS6) sticks. The newly 
identified binding determinant T1143, located at the base of the selectivity filter in domain III 
is shown in green. Black dots represent hydrogen bonds between diltiazem (blue sticks) and 
T1143 and Y1463. 
B, Agreement between the QSAR features (Corelli et al, 1997) and the best docking pose. 
Hydrophobic interactions are marked grey; polar interacting regions are shaded green. The 
distance between the two hydrogen bonding features is approximately 8 Å.  The location of 
the positive charge is marked with an asterix. 
 
 
3.4 DISCUSSION 
3.4.1 Threonine 1143 is a strong determinant of Dil sensitivity. 
We have previously shown that qDil accesses its binding site in the open channel pore from 
the intracellular site in a use-dependent manner (Shabbir et al 2010). Here we made use of Dil 
and qDil to identify additional binding determinants for this clinically important drug. 
Structure-activity relationship studies of BTZ suggest the importance of 2 H-bonds for high 
affinity block (e.g. (Das et al. 1992; Floyd et al. 1992; Kimball et al. 1992), Consequently we 
focused on polar residues surrounding an in silico binding pocket that was designed based on 
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previous work of (Tikhonov and Zhorov 2008). Out of the three identified candidate residues, 
mutation T1143A almost completely eliminated channel inhibition by qDil and Dil, while the 
other mutations (T1067A, S1142A) had no effect (Fig. 2C). At 300 µM Dil, T1143A 
completely stopped use-dependent channel block at 1 Hz (Fig. 6). The concentration-
inhibition relationship for Cav1.2 incorporating the β2a-subunit at low frequency (0.05 Hz) is 
illustrated in Fig. 8. Channel block at the highest concentration applied (500 µM) was 70±5.0 
%. To our knowledge this is the strongest effect on Dil sensitivity reported for a single amino 
acid mutation (Hockerman et al. 2000).  
 
Fig 8.  Diltiazem block of WT and T1143A 
The IC50 values control to 500µM [d-cis-diltiazem: 95 ± 5 mM (data from shabbir et al 2010) 
(Hill slope nH = 1.6 _ 0.4 ) WT and T1143A  were obtained by fitting the data points  to the 
Hill equation (as described in Methods). Channel block was estimated as peak IBa inhibition 
during trains of 20 pulses (0.2 Hz, 100 ms) applied from a holding potential of -80 mV to +20 
mV in control (Table 2).  
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Table 2.  Peak current decay in the absence of drug after 20 pulses (100 ms) at 0.2 Hz 
Mutation Control inhibition, % 
WT 5.9 ± 3.4 
T1143E 6.3 ± 1.3 
T1143V 6.1 ± 0.2 
T1143C 2.2 ± 1.6 
T1143N 13.1 ± 0.1 
T1143S 9.4 ± 0.6 
T1143Y 35.1 ± 0.1 
T1143A 7.5 ± 3.1 
T1143L 16.1 ± 0.3 
S1142A 6.2 ± 3.3 
T1067A 5.5 ± 3.1 
 
 
 
 
T1143 was suggested to interact with the BTZ SQ32910 by (Tikhonov and Zhorov 2008) 
using an in silico docking approach. In our homology model, T1143 lies in close proximity 
with previously identified binding modulating residues E1118 and F1117 from the selectivity 
filter (Fig. 1). Interestingly, it was previously reported that T1143A reduces IBa inhibition by 
verapamil during a 1-Hz train by approximately 25% (Dilmac et al. 2004). We have 
confirmed this finding making use of quaternary devapamil (100 µM) applied via the pipette 
(Fig. 9).  
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Fig 9. T1143A diminish the Use dependent block of qD888 
A,use-dependent inhibition of wild-type and mutant channels was measured in the absence  or 
presence of 100 µM  qD888 in the pipette (intracellular) solution. Channel block was 
estimated as peak IBa inhibition during trains of 20 pulses (0.2 Hz, 100 ms) applied from a 
holding potential of -80 mV to +20 mVB, Remaining currents after 20 pulses in WT and the 
indicated mutants.  
 
 
Taken together, these findings indicate that T1143 forms part of the PAA and Dil binding 
sites. However, substitution of this residue by alanine has a much stronger effect on channel 
block by Dil than by by PAAs. This data suggests that T1143 is essential for binding of Dil 
and less important for channel inhibition by PAAs. Comparison of the binding modes 
proposed by docking simulations provides a rationale for the different effects of T1143. While 
T1143 and Y1463 seem to be important anchors for Dil, phenyalalkylamines such as 
verapamil or quaternary devapamil are apparently anchored in the cavity by formation of 
hydrogen bonds with Y1463 and Y1152 (IIIS6) Fig 10. 
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Fig 10. Hydrogen bonding  of  Tyrosines with IIIS6 and IVS6  
A, Superposition of original IIIP loop (dark orange) and slightly shifted IIIP loop (light 
orange).  
B, the modifications lead to improved hydrogen bonding networks (green) between segments 
III-S5, III-P, III-S6, and IV-S6. New hydrogen bonds are formed between Q1070 (IIIS5) and 
S1142 and T1143 (IIISF). The hydroxyl group of Y1152 (IIIS6) binds to the hydroxyl group 
of S1142 (IIISF) and the backbone carbonyl oxygen of V1141 (C-terminus of III-P helix). 
The hydroxyl group of Y1463 (IVS6) binds to the hydroxyl group of T1066 (IIIS5) and 
backbone oxygen atom of T1067. 
 
3.4.2 T1143A displays wild type kinetics. 
Changes in channel gating have been shown to affect channel inhibition by calcium 
antagonists (Berjukow et al. 2000; Sokolov et al. 2001). We therefore carefully studied the 
kinetics of mutant T1143A. Fig. 5 illustrates that introduction of an alanine in position T1143 
affected neither the channel’s activation nor its inactivation properties. Both curves were 
indistinguishable from wild type (see also Table 3). This finding supports the view that 
reduced channel block caused by T1143A reflects reduced affinity of Dil to its binding pocket 
and not an allosteric modulation. 
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Table 3  
Midpoints and slope factors of the activation and inactivation curves. 
Mutation V0.5,act , mV kact , mV V0.5,inact , mV kinact , mV 
WT -6.5 ± 0.7 5.4 ± 0.9 -42.8 ± 0.8 6.6 ± 0.7 
T1143A -5.7 ± 0.7 6.6 ± 0.6 -43.7 ± 0.7 7.5 ± 0.7 
T1143C 2.4 ± 0.7 7.6 ± 0.7 -19.3 ± 0.9 10.5 ± 1.0 
T1143E -8.3 ± 0.7 5.6 ± 0.7 -21.5 ± 0.8 7.3 ± 0.7 
T1143V -1.0 ± 0.7 9.5 ± 0.7 -26.2 ± 0.9 13 ± 0.8 
T1143L -24.1 ± 0.7 8.9 ± 0.6 -25.7 ± 1.3 12.6 ± 1.1 
T1143N -6.7 ± 0.7 7.6 ± 0.7 -22.5 ± 1.0 12.9 ± 0.8 
T1143S -9.4 ± 1.14 4.6 ± 0.5 -34.4 ± 0.9 10.7 ± 0.9 
T1143Y -26.1 ± 0.8 6.0 ± 0.7 -42.4 ± 1.3 11.4 ± 1.1 
 
 
3.4.3 Other substitutions of T1143 affect channel inactivation. 
In order to establish a link between amino acid properties and channel block we substituted 
T1143 by residues with different physicochemical properties, including for example different 
hydrogen bonding capabilities, size and polarity. All mutations (except the above mentioned 
alanine) shifted the inactivation curve to more depolarised voltages. Reduced inactivation 
during a test pulse may thus have affected channel block. Hence, it can not be excluded that 
some of the observed reduction in use-dependent channel inhibition in mutants 
T1143E/V/C/N/S can be attributed to removal of channel inactivation via an allosteric 
mechanism and not to reduction of affinity. 
This is, however, not the case for T1143A displaying similar kinetics to wild type (Fig. 5). 
We speculate that T1143 provides a second hydrogen bond (additionally to Y1463), necessary 
for high-affinity diltiazem block. Docking studies with the T1143A mutant support the 
hypothesis that T1143 together with Y1463 serve as anchor points for diltiazem via H-bond 
formation (see Fig. 7A,B). Fig. 11 shows the best binding pose obtained with the T1143A 
mutant channel.  
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Mutations T1143S and T1143Y did not restore WT-like behaviour, although these residues 
possess hydroxyl groups similar to threonine. Apart from the reduction in inactivation both 
residues have changed side chain sizes compared to the small T1143. The larger size of these 
residues may prevent a high-affinity fit of Dil into its binding site.  
                              A                                               B 
 
Fig. 11 Docking poses in WT and T1143A models. 
A) Hydrogen bonds between diltiazem (green stick representation) and T1143 (yellow sticks) 
and Y1463 (purple sticks) are shown as black dotted lines. B) In the T1143A mutant no 
hydrogen bonds are predicted between diltiazem and Cav1.2.  
 
 
.  
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4 SUMMARY OF THE THESIS 
Quaternary derivative d-cis-diltiazem inhibited Ca(V)1.2 when applied to the intracellular 
side of the membrane in a use-dependent manner and induced only a low level of tonic (non-
use-dependent) block when applied to the extracellular side of the membrane. The latter 
finding suggests an intracellular access path of Dil to its binding site (Shabbier et al. BJP 
2011). Data of my second study demonstrate: i) strong reduction of use-dependent and resting 
state IBa inhibition by Dil and qDil when a threonine in the selectivity filter of domain III 
(T1143) is mutated to alanine. The alanine mutation (T1143A) had no effect on current 
kinetics suggesting that T1143 forms a binding determinant for Dil and qDil).  
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